Coherus_Logo_RGB_150.png
Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024
30 oct. 2024 16h20 HE | Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its third quarter 2024 financial results will be released after...
Coherus_Logo_RGB_150.png
Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update
08 août 2024 16h05 HE | Coherus BioSciences, Inc.
– Net revenue of $65.0 million in Q2 2024 – – CHS-114 Phase 1 Study Recruitment Continues into Expansion Cohorts in Head and Neck Cancer in Combination with LOQTORZI – – Bryan McMichael Appointed as...
Coherus_Logo_RGB_150.png
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
27 juin 2024 08h26 HE | Coherus BioSciences, Inc.
REDWOOD CITY, Calif., June 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced it agreed to divest YUSIMRY (adalimumab-aqvh) to Hong Kong King-Friend...
Rita_Karachun
Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors
05 juin 2024 09h00 HE | Coherus BioSciences, Inc.
REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq: CHRS) today announced that Rita Karachun, CPA, CGMA, most recently Senior Vice...
Coherus_Logo_RGB_150.png
Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference
30 mai 2024 09h00 HE | Coherus BioSciences, Inc.
REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the 2024 Jefferies Global Healthcare...
Coherus_Logo_RGB_150.png
Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA
23 mai 2024 09h00 HE | Coherus BioSciences, Inc.
REDWOOD CITY, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the upcoming TD Cowen 5th Annual...
Coherus_Logo_RGB_150.png
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
09 mai 2024 16h01 HE | Coherus BioSciences, Inc.
 – Net revenue of $77.1 million in Q1 2024 –  – CRI and ENB Therapeutics development partnership for toripalimab in ovarian cancer – – New debt and royalty financing replaces $75 million...
Coherus_Logo_RGB_150.png
Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan
09 mai 2024 07h30 HE | Coherus BioSciences, Inc.
– New $38.7 million term loan with a May 2029 maturity –– $37.5 million royalty monetization financing based on future sales of LOQTORZI® and UDENYCA® –  REDWOOD CITY, Calif., May 09, 2024 (GLOBE...
Coherus_Logo_RGB_150.png
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
24 avr. 2024 10h02 HE | Coherus BioSciences, Inc.
REDWOOD CITY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the first presentation of clinical data for CHS-114, a highly selective...
Coherus_Logo_RGB_150.png
Coherus Completes Divestiture of Ophthalmology Franchise
04 mars 2024 01h00 HE | Coherus BioSciences, Inc.
– Upfront cash payment of $170 million strengthens capital structure – – Transaction solidifies Coherus’ strategic focus in oncology – REDWOOD CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) --...